Vanguard Group
PRLD icon

Vanguard Group’s Prelude Therapeutics PRLD Stock Holding History

Vanguard Group’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$4.1M Buy
1,413,986
+421,132
+42% +$711K ﹤0.01% 3329
2025
Q3 		$1.43M Buy
992,854
+60,284
+6% +$60.4K ﹤0.01% 3674
2025
Q2 		$754K Sell
932,570
-76,634
-8% -$66.4K ﹤0.01% 3823
2025
Q1 		$775K Sell
1,009,204
-1,188
-0.1% -$1.11K ﹤0.01% 3784
2024
Q4 		$1.29M Sell
1,010,392
-11,378
-1% -$15.1K ﹤0.01% 3685
2024
Q3 		$2.12M Buy
1,021,770
+11,205
+1% +$51.9K ﹤0.01% 3544
2024
Q2 		$3.85M Sell
1,010,565
-6,434
-0.6% -$26.2K ﹤0.01% 3363
2024
Q1 		$4.82M Buy
1,016,999
+10,143
+1% +$39.5K ﹤0.01% 3313
2023
Q4 		$4.3M Buy
1,006,856
+33,250
+3% +$101K ﹤0.01% 3344
2023
Q3 		$3.01M Buy
973,606
+20,668
+2% +$77.6K ﹤0.01% 3455
2023
Q2 		$4.29M Buy
952,938
+36,924
+4% +$221K ﹤0.01% 3380
2023
Q1 		$5.22M Buy
916,014
+16,700
+2% +$102K ﹤0.01% 3290
2022
Q4 		$5.43M Buy
899,314
+269
+0% +$1.72K ﹤0.01% 3264
2022
Q3 		$5.94M Hold
899,045
– – ﹤0.01% 3226
2022
Q2 		$4.69M Buy
899,045
+98,547
+12% +$502K ﹤0.01% 3411
2022
Q1 		$5.52M Buy
800,498
+29,058
+4% +$266K ﹤0.01% 3478
2021
Q4 		$9.6M Sell
771,440
-365,282
-32% -$5.94M ﹤0.01% 3230
2021
Q3 		$35.5M Buy
1,136,722
+10,675
+0.9% +$346K ﹤0.01% 2548
2021
Q2 		$32.2M Buy
1,126,047
+258,627
+30% +$9.21M ﹤0.01% 2593
2021
Q1 		$37.6M Buy
867,420
+207,575
+31% +$13.8M ﹤0.01% 2459
2020
Q4 		$47.2M Buy
659,845
+614,845
+1,366% +$30.6M ﹤0.01% 2228
2020
Q3 		$1.36M Buy
+45,000
New +$1.27M ﹤0.01% 3593

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group's PRLD Position: Q4 2025 in Review

Vanguard Group increased its Prelude Therapeutics (PRLD) stake by 42% in Q4 2025, buying an estimated $711K and bringing the position to 1,413,986 shares worth $4.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3329.

Vanguard Group first reported a position in PRLD in Q3 2020 and has held it in 22 quarters since. The position peaked at $47.2M in Q4 2020. 48 funds tracked by Wall St. Rank hold PRLD as of Q4 2025.

  • Vanguard Group held 1,413,986 shares of Prelude Therapeutics worth $4.1M as of Q4 2025.
  • Vanguard Group bought 421,132 Prelude Therapeutics shares in Q4 2025, an estimated $711K.
  • Prelude Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3329 holding.
  • Vanguard Group first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • Vanguard Group's Prelude Therapeutics position peaked at $47.2M in Q4 2020.
  • 48 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.